Anakinra
- Generic Name
- Anakinra
- Brand Names
- Kineret
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 143090-92-0
- Unique Ingredient Identifier
- 9013DUQ28K
- Background
Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the managemen...
- Indication
Anakinra is an interleukin-1 receptor antagonist indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis (RA), in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs). Anakinra can be used alone or in combin...
- Associated Conditions
- Coronavirus Disease 2019 (COVID‑19), Cryopyrin-associated Periodic Syndromes (CAPS), Deficiency of the interleukin-1 receptor antagonist, Idiopathic Recurrent Pericarditis, Moderately to Severely Active Rheumatoid Arthritis, Neonatal-Onset Multisystem Inflammatory Disease (NOMID), Systemic Juvenile Idiopathic Arthritis (SJIA)
- Associated Therapies
- -
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
- Conditions
- Interventions
- Other: No systemic corticosteroidOther: No antiviral agent for COVID-19Other: No immune modulation for COVID-19Drug: Standard course macrolideOther: No antiviral agent for influenzaDrug: Local standard venous thromboprophylaxisOther: No immunoglobulinOther: No simvastatinOther: No cysteamineOther: No Immune Modulator for InfluenzaOther: No vitamin COther: No antiplateletProcedure: Clinician-preferred mechanical ventilation strategyOther: No renin-angiotensin system inhibitorOther: No endothelial modulatorDrug: CeftriaxoneDrug: Moxifloxacin or LevofloxacinDrug: Extended course macrolideDrug: Fixed-duration HydrocortisoneDrug: Five-days oseltamivirDrug: Lopinavir / RitonavirBiological: Convalescent plasmaDrug: Angiotensin converting enzyme inhibitorDrug: Nirmatrelvir/ritonavirDrug: Therapeutic dose anticoagulationProcedure: Protocolised mechanical ventilation strategyDrug: Interferon beta-1aDrug: Vitamin CDrug: SimvastatinDrug: AspirinDrug: EritoranDrug: CysteamineDrug: ImatinibDrug: Shock-dependent hydrocortisoneDrug: Ten-days oseltamivirDrug: P2Y12 inhibitorDrug: Angiotensin Receptor BlockersDrug: Conventional low dose thromboprophylaxisBiological: Delayed administration of convalescent plasmaDrug: Piperacillin-tazobactamDrug: HydroxychloroquineDrug: AnakinraDrug: ApremilastDrug: BaricitinibDrug: RemdesivirDrug: Fixed-duration higher dose HydrocortisoneDrug: Hydroxychloroquine + lopinavir/ritonavirDrug: Intermediate dose thromboprophylaxisDrug: Nirmatrelvir/ritonavir + remdesivirDrug: ARB + DMX-200Drug: CeftarolineDrug: Baloxavir MarboxilDrug: TocilizumabDrug: Amoxicillin-clavulanateDrug: Fixed-duration dexamethasoneDrug: Five-days oseltamivir + baloxavir marboxilDrug: Continuation of therapeutic dose anticoagulationDrug: IvermectinDrug: SarilumabDrug: Ten-days oseltamivir + baloxavir marboxil
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- UMC Utrecht
- Target Recruit Count
- 20000
- Registration Number
- NCT02735707
- Locations
- 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada
🇺🇸University of Illinois Health, Chicago, Illinois, United States
🇦🇺Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia
Effects of Interleukin-1 Beta on Low Testosterone Levels in Men With Obesity and Metabolic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2016-02-03
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 70
- Registration Number
- NCT02672592
- Locations
- 🇨🇭
University Department of Medicine, Kantonsspital Aarau, Aarau, Switzerland
🇨🇭University Hospital Basel, Basel, Switzerland
Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2021-06-22
- Lead Sponsor
- Baylor Research Institute
- Target Recruit Count
- 20
- Registration Number
- NCT02550327
- Locations
- 🇺🇸
Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
Interleukin-1 Receptor Antagonist for the Treatment of Heart Failure in Patients With Left Ventricular Assist Devices
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 10
- Registration Number
- NCT02547766
- Locations
- 🇺🇸
University of Utah, Salt Lake City, Utah, United States
Anakinra, A Recombinant Human IL-1 Receptor Antagonist for Neuroinflammation in HIV-1 Infection
- Conditions
- First Posted Date
- 2015-08-19
- Last Posted Date
- 2019-11-29
- Target Recruit Count
- 1
- Registration Number
- NCT02527460
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Study of the Effects of Anakinra in Corticosteroid-resistant Subjects With Sudden Sensorineural Hearing Loss
- First Posted Date
- 2015-04-10
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- Andrea Vambutas
- Target Recruit Count
- 2
- Registration Number
- NCT02414152
- Locations
- 🇺🇸
North Shore-LIJ Hearing and Speech Center, New Hyde Park, New York, United States
Anakinra and Kawasaki Disease
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2019-07-02
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 16
- Registration Number
- NCT02390596
- Locations
- 🇫🇷
AP-HP,Bicêtre Hospital, Le Kremlin-Bicêtre, France
Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2
- First Posted Date
- 2014-10-30
- Last Posted Date
- 2018-04-02
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 33
- Registration Number
- NCT02278562
- Locations
- 🇺🇸
Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville, Tennessee, United States
Treatment of Refractory Hemochromatosis Rheumatism by Anakinra: a Preliminary Phase II Study
- First Posted Date
- 2014-10-13
- Last Posted Date
- 2019-03-12
- Lead Sponsor
- Rennes University Hospital
- Target Recruit Count
- 17
- Registration Number
- NCT02263638
- Locations
- 🇫🇷
Groupe Hospitalier Lariboisière, Paris, France
🇫🇷Rennes University Hospital, Rennes, France
🇫🇷CHRU de Lille, Lille, France
Clinical Study to Evaluate the Efficacy of Anakinra in Patients With Rheumatoid Arthritis and Diabetes
- Conditions
- Interventions
- First Posted Date
- 2014-09-10
- Last Posted Date
- 2018-12-14
- Lead Sponsor
- Prof. Roberto Giacomelli
- Target Recruit Count
- 41
- Registration Number
- NCT02236481
- Locations
- 🇮🇹
L'Aquila University, L'Aquila, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.